Complementary and Alternative Medicine Use for Vasomotor Symptoms Among Women Who Have Discontinued Hormone Therapy

Duramed Research, Inc., Medical Affairs, Bala Cynwyd, PA, USA.
Journal of Obstetric Gynecologic & Neonatal Nursing (Impact Factor: 1.02). 02/2009; 38(1):50-9. DOI: 10.1111/j.1552-6909.2008.00305.x
Source: PubMed


To explore the use and perceived usefulness of complementary and alternative medicine therapies and nonhormonal conventional medicine alternatives to treat vasomotor symptoms occurring after withdrawal from hormone therapy.
Retrospective, single cross sectional descriptive study.
Study volunteers were recruited via a direct mailed questionnaire sent to a sample of women throughout the United States. Additional respondents were recruited through flyers and postcards advertising the study placed with permission at several health care provider offices and other locations.
A sample of 563 menopausal women who had discontinued the use of hormone therapy completed a questionnaire describing their experiences with the use of complementary and alternative medicine.
Responses to an investigator developed survey.
Nearly half of the women surveyed used complementary and alternative medicine. The most common choices of complementary and alternative medicine were (a) multivitamins and calcium, (b) black cohosh, (c) soy supplements and food, (d) antidepressants, (e) meditation and relaxation, (f) evening primrose oil, (g) antihypertensives, and (h) homeopathy. Of the alternative therapies that were used by at least 5% of the sample, antidepressants were perceived as the most useful.
With the increased adoption of complementary and alternative medicine, it is important for health care providers to be familiar with the various methods so they are comfortable discussing the benefits and risks with their patients to assist them in making informed decisions.

Download full-text


Available from: Heather Becker, Sep 29, 2014
  • Source
    • "The predicted increase in the incidence of osteoporosis in women justifies a search for opportunities to prevent bone fractures (Wadolowska et al., 2013). Consequently, there has been a vast increase in the use of natural products that could provide all of the benefits but none of the risks of prescription drugs (Kupferer et al., 2009). Many therapeutic strategies tend to focus on calcium supplements for prevention and treatment of osteoporosis instead of hormone replacement therapy (Wallace et al., 2004; Shaker et al., 2005). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The efficacy of Coelatura aegyptiaca shell powder (CES, 500 mg/kg BW) was evaluated as a calcium supplement in ovariectomized (OVX) rats for ten weeks of treatment. The biochemical components and the antioxidant properties of the shell powder were determined. The bone mineral density (BMD), bone mineral content (BMC), calcium (Ca) and phosphorus (P) contents in serum and bone, serum total alkaline phosphatase (TALP) and bone alkaline phosphatase (BALP), serum calcitonin and parathyroid (PTH) hormones were determined. Furthermore, some of the oxidative stress markers [malondialdehyde (MDA), superoxide dismutase (SOD), glutathione peroxidase (GPx) and total antioxidant capacity (TAC)] were estimated in bone. The current study revealed that CES contained 19.38% Ca, 0.315% P as well as some of antioxidant amino acids which have a potent antioxidant activity against 1,1-diphenylpicrylhydrazyl (DPPH) free radical. Administration of CES to OVX rats increased BMD, BMC, tibial Ca and P contents and BALP activity, as compared to OVX rats. An ameliorative effect was recorded in the levels of calcitonin, PTH, MDA, SOD, GPx and TAC subsequent to CES administration to OVX rats.This ameliorative effect of CES powder against osteoporosis may be attributed to its antioxidant efficacy and/or to its Ca content. In conclusion, CES may have the potential to develop a clinically useful anti-osteoporotic agent, since its effect was comparable with alendronate (6.5 mg/kg BW/week).
    Full-text · Article · Sep 2013
  • Source
    • "There are many factors impacting the outcome of CHM or TCM psychotherapy in the treatment of menopausal syndrome, such as the selection of formulae and course of treatment, among others. Generally, there is a lack of long-term followup beyond the trial duration of 6–12 weeks, and well-designed, randomized controlled trials are needed to elucidate the true effects of these therapies beyond the placebo effect [34, 35]. Additionally, the insufficient manifestation of effectiveness in PSY and CHM alone group is possibly due to the inadequate sample size; after P value adjustment with Bonferroni method, significant difference can only be detected between the PSY + CHM group and placebo group, although the average KI scores in each group indicated a better trend of effect in PSY group compared with placebo group and CHM added-on groups compared with no CHM groups (PSY + CHM versus PSY alone or CHM alone vs placebo), thus future studies with larger sample size are still warranted to clarify the superiority of TCM based psychotherapy and CHM alone therapy for menopause syndrome. "
    [Show abstract] [Hide abstract]
    ABSTRACT: This multicenter, randomized, controlled clinical study was designed to address the effectiveness of combined traditional-Chinese-medicine- (TCM-) based psychotherapy and Chinese herbal medicine (CHM) in the treatment of menopausal syndrome. Altogether 424 eligible women diagnosed as menopausal syndrome and categorized as Kidney-Yin/Kidney-Yang deficiency pattern in TCM were randomly assigned into 4 groups and accepted TCM-based psychotherapy (PSY), CHM, PSY + CHM, or placebo therapies, respectively, for 12 weeks, and another 12 weeks were taken as the followup. Kupperman Index (KI) and the Menopause-Specific Quality of Life (MENQOL) with its four subscales (vasomotor, physical, psychosocial, and sexual) were employed for efficacy assessment. Results showed that 400 participants completed 12-week treatment, of which 380 finished the record of KI and MENQOF at week 24. The average adjusted number of KI score decreased between baseline and 12 weeks in all groups. Statistically significant differences were detected in the average adjusted change between the PSY + CHM group and placebo at overall time points (P < 0.05). No severe adverse events occurred in each group and no significant differences were indicated between any of the three groups and placebo in adverse event proportion. We concluded that TCM psychotherapy combined with CHM has a favorable outcome in treating menopausal syndrome.
    Full-text · Article · Dec 2012 · Evidence-based Complementary and Alternative Medicine
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recent large clinical trials demonstrating deleterious effects of postmenopausal hormone replacement therapy have raised interest in the use of food products and extracts containing phytoestrogens as potential safe alternatives for menopausal symptoms, age-related cognitive decline and neurodegenerative diseases. While numerous preclinical studies and various clinical trials point to beneficial effects of estrogens on the brain, phytoestrogens from several sources share many of these estrogenic effects, in addition to having unique activities distinct from natural estrogens. Numerous in vitro and in vivo studies show potential neuroprotective properties of phytoestrogens on the brain in conditions ranging from aging to neurodegenerative disease and cerebral ischemia. Although dosage, timing and safety concerns remain to be addressed before their therapeutic use in human populations can be recommended, their safety profile and some intriguing studies on human cognition in aging suggest that further clinical study of these compounds for brain health is warranted.
    No preview · Article · Aug 2009 · Drugs of today (Barcelona, Spain: 1998)
Show more